Growth Hormone · researchUpdated Nov 2026

Tesamorelin + Ipamorelin Blend Dosage & Reconstitution Protocol

Tesamorelin Acetate + Ipamorelin Blend

A 10 mg/5 mg pre-mixed vial pairing tesamorelin, the GHRH analog with the strongest clinical evidence for visceral fat reduction, with ipamorelin as the ghrelin-receptor partner. The 2:1 ratio keeps tesamorelin as the primary driver while ipamorelin sharpens the GH pulse, making it the blend most often chosen for stubborn abdominal fat.

Typical Dose
750 mcg-1.5 mg
Frequency
Daily at bedtime
Cycle Length
8–12 weeks
Administration
subcutaneous
Tesamorelin + Ipamorelin Blend lyophilized reference vialTesamorelin + Ipamorelin Blend Reference Vial
Lyophilized Powder · U-100 Syringe ReferenceCalculate Draw ↓

Multi-Peptide Vial Composition

Tesamorelin + Ipamorelin Blend Active Blend Ratio

Tesamorelin + Ipamorelin Blend Quick Reference

Select your vial strength to update all reference concentrations, dosage tables, and syringe draws on this page.

Vial strength:
Tesamorelin + Ipamorelin Blend Quick Reference (15 mg Vial)100 units = 1.0 mL · 1 unit = 0.01 mL
Vial contents
15 mg Tesamorelin + Ipamorelin Blend
Final volume (Bacteriostatic Water)
2 mL (200 units)
Concentration
7.5 mg/mL
One U-100 syringe unit
75 mcg in 0.01 mL

Arithmetic summary: Reconstituting a 15 mg Tesamorelin + Ipamorelin Blend vial with 2 mL of bacteriostatic water yields 7.5 mg/mL. Every 10 units (0.10 mL) on a U-100 insulin syringe delivers 750 mcg.

Tesamorelin + Ipamorelin Blend 15 mg lyophilized reference vialTesamorelin + Ipamorelin Blend · 15 mg Vial

How Much To Draw

Select a row to preview the draw on the syringe. Values are reference figures from the literature, not medical advice.

15 mg Vial · 2 mL BAC Water · 75 mcg Per Unit
PhaseDosemLUnitsDoses
BeginnerOnce nightly · Weeks 1–2750 mcg (500 Tesa / 250 Ipa)0.101020
StandardOnce nightly · Weeks 3–41.5 mg (1 mg Tesa / 500 Ipa)0.202010
TargetOnce nightly · Weeks 5–8+2.25 mg (1.5 mg Tesa / 750 Ipa)0.30306
  • The 2:1 ratio is fixed by the vial, so a 1.5 mg dose delivers 1 mg tesamorelin + 0.5 mg ipamorelin. Dosed nightly, fasted.
  • Reconstituted vials are generally used within 28–30 days refrigerated, so supply plans allow at least one vial per 4 weeks even when a vial holds more doses.

Interactive U-100 Syringe Scale

U-100 syringe drawn to 10 units (0.10 mL), 750 mcg (500 Tesa / 250 Ipa).

Click any dosing tier row above to preview that exact draw on the U-100 syringe scale.

How To Reconstitute Tesamorelin + Ipamorelin Blend

Four steps, in order. Work on a clean surface with washed hands and swab every vial top with alcohol first.

Get Lab-Tested Vials & BAC Water at ASCND Bio →
  1. Step 1: Drawing bacteriostatic water into a sterile U-100 syringeStep 01

    Draw Bacteriostatic Water

    Draw 2 mL of bacteriostatic water (0.9% benzyl alcohol) into a sterile syringe. Use bacteriostatic, not plain sterile water, so the multi-dose vial stays preserved between draws.

  2. Step 2: Injecting bacteriostatic water slowly down the inside glass wall of the peptide vialStep 02

    Equalize & Trickle Down The Glass Wall

    Pierce the stopper and angle the needle at 45° so the water runs slowly down the inside glass wall. Never spray directly onto the lyophilized puck: the jet foams the solution and can denature fragile peptide chains.

  3. Step 3: Gently rolling the peptide vial between fingertips until completely dissolvedStep 03

    Gently Roll, Never Shake

    Roll the vial gently between your fingers or swirl in a slow circle until the liquid is 100% clear with no undissolved particles. Shaking shears peptide bonds and traps air bubbles; if it clouds, let it rest in the fridge for 15 minutes.

  4. Step 4: Storing reconstituted peptide vials upright at 2 to 8 degrees CelsiusStep 04

    Label & Store At 2–8 °C (36–46 °F)

    Write the reconstitution date and concentration on the vial. Refrigerate upright at 2–8 °C (36–46 °F), protected from light, and use within 28–30 days. Do not freeze the reconstituted liquid.

Reconstitution & Dosage CalculatorU-100 Scale (100 units = 1.0 mL · 1 unit = 0.01 mL)

Tesamorelin + Ipamorelin Blend Reconstitution & Dosage Calculator

Convert a lyophilized peptide vial amount and bacteriostatic water volume into a reconstitution concentration, then translate your protocol dose and schedule into exact U-100 syringe units and multi-week vial supplies.

1Enter Vial & Water: Enter the peptide amount in your vial (mg) and bacteriostatic water volume (mL), or click Recommend Water.
2Enter Dose & Schedule: Enter your target dose in mcg or mg, pick your dosing schedule, and choose your U-100 syringe barrel.
3Follow Draw & Mixing Plan: Read the exact U-100 unit mark on the syringe, 4-step reconstitution instructions, and vials required.
1

Reconstitution

Enter the peptide amount in the vial and the volume of bacteriostatic or sterile water you plan to add.

mg
mL

Concentration

How much peptide each mL of solution contains after mixing.

5 mg/mL

Per 1 unit (0.01 mL)50 mcg
Per 10 units (0.1 mL)500 mcg
2

Your Dose & Schedule

Enter the dose from your protocol, select your dosing schedule, and pick the insulin syringe you are using.

1 mg = 1,000 mcg
Insulin syringe (U-100)

100-unit (1 mL): marks every 2 units. Standard barrel for draws up to 100 units.

Your Draw & Reconstitution Plan

✓ Aligns cleanly on graduation mark

Draw to

5units

Pull plunger seal to line 5

Volume

0.05 mL

Delivers 250 mcg

Doses per vial

20

Lasts 20 days (Once daily)

4-Week Schedule Supply

2 vials

28 doses · 2.0 mL BAC water

To-Scale U-100 Insulin Syringe (100-Unit / 1.0 mL Barrel)Read volume at the leading edge of the black plunger seal facing the needle
10 units

How to Reconstitute for Your Dosage Schedule

Once Daily
  1. 1Equilibrate & Sanitize: Remove your 5 mg vial from freezer storage and allow it to equilibrate at room temperature for 15–20 minutes. Swab both stoppers with 70% isopropyl alcohol.
  2. 2Draw & Inject Diluent Down Wall: Draw 1.0 mL (100 units) of bacteriostatic water and inject slowly down the inside glass wall at a 45° angle to prevent foaming.
  3. 3Swirl Gently & Refrigerate: Gently swirl or roll until dissolved (do not shake). Your concentration is 5 mg/mL (50 mcg/unit). Label and refrigerate at 2–8 °C.
  4. 4Draw Your Scheduled Dose: For each 250 mcg injection, pull the plunger to 5 units (0.05 mL) on your U-100 syringe.

Supplies Needed by Schedule Duration

5 mg vial · 250 mcg/dose
DurationTotal PeptideVials RequiredU-100 SyringesBAC Water

For educational and research calculations only. Always confirm calculations independently before use.

Supplies Needed for Tesamorelin + Ipamorelin Blend

Plan vials, U-100 insulin syringes, bacteriostatic water, and sterile alcohol prep pads by protocol duration.

Bacteriostatic water, lyophilized peptide vial, U-100 insulin syringes, and sterile alcohol prep pads
4 Core Supplies: 15 mg Tesamorelin + Ipamorelin Blend vials, Bacteriostatic Water (0.9% benzyl alcohol), U-100 insulin syringes, and 70% isopropyl alcohol pads.

1-, 2-, and 4-Week Supply Reference (15 mg Vial Format)

1.5 mg (1 mg Tesa / 500 Ipa) · Once nightly

Tesamorelin + Ipamorelin Blend Vials (15 mg each):

  • 1 week (10.5 mg total):1 vial required
  • 2 weeks (21 mg total):2 vials required
  • 4 weeks (42 mg total):3 vials required

U-100 Insulin Syringes & Alcohol Pads:

  • 1 week:7 syringes · 14 pads
  • 2 weeks:14 syringes · 28 pads
  • 4 weeks:28 syringes · 56 pads

8 Weeks

15 mg Vial
VialsTesamorelin + Ipamorelin Blend mg vials
10
U-100 Syringesone sterile syringe per dose
66
BAC Water30 mL multi-dose vials
2
Alcohol Padsvial stopper + skin prep
122

56 total doses over 8 weeks

12 Weeks

15 mg Vial
VialsTesamorelin + Ipamorelin Blend mg vials
14
U-100 Syringesone sterile syringe per dose
98
BAC Water30 mL multi-dose vials
3
Alcohol Padsvial stopper + skin prep
182

84 total doses over 12 weeks

16 Weeks

15 mg Vial
VialsTesamorelin + Ipamorelin Blend mg vials
19
U-100 Syringesone sterile syringe per dose
131
BAC Water30 mL multi-dose vials
4
Alcohol Padsvial stopper + skin prep
243

112 total doses over 16 weeks

Synergistic Protocols

Popular Tesamorelin + Ipamorelin Blend Stacks & Co-Administration

Common research and clinical combinations pairing Tesamorelin + Ipamorelin Blend with complementary pathways.

Dual-Pathway Pulsatile GH Secretagogue StackCycle: 5 days on / 2 days off for 12–16 weeks · 4 weeks off

CJC-1295 (No DAC / Mod GRF 1-29) + Ipamorelin

Pairs a GHRH analog (amplifying pulse peak) with a selective ghrelin mimetic (initiating pulse release without cortisol or prolactin spikes).

CompoundProtocol DoseTiming & Route
CJC-1295 (No DAC)100–200 mcg per injectionNightly before bed (90+ min fasted)
Ipamorelin100–200 mcg per injectionCo-administered nightly (optional AM fasted pulse)

Stacking Note: Carbohydrates and dietary fats blunt GH release; administer at least 90–120 minutes after your final evening meal.

Targeted Visceral Fat & IGF-1 OptimizationCycle: 8–12 weeks on · 4 weeks off

Tesamorelin + Ipamorelin Visceral Adipose Stack

Combines FDA-studied GHRH analog Tesamorelin (selective trunk/visceral adipose lipolysis) with a nighttime Ipamorelin pulse.

CompoundProtocol DoseTiming & Route
Tesamorelin1.0–2.0 mg once dailyMorning fasted or pre-bed SubQ
Ipamorelin100–200 mcg once dailyPre-bed fasted SubQ

Stacking Note: Monitor fasting glucose and serum IGF-1 levels at baseline and week 8.

Accelerated Structural & Tendon RemodelingCycle: 12 weeks on · 4 weeks off

GH Secretagogue + BPC-157 Connective Tissue Stack

Systemic GH/IGF-1 elevation upregulates collagen synthesis while BPC-157 increases local growth hormone receptor expression on fibroblasts.

CompoundProtocol DoseTiming & Route
Sermorelin or CJC-1295/Ipamorelin200–300 mcg nightlyPre-bed fasted SubQ
BPC-157250–500 mcg dailyMorning or post-training SubQ

Stacking Note: One of the most widely studied clinical combinations for post-surgical and athletic soft-tissue recovery.

Subcutaneous Injection Sites & Storage

Rotate sites with every injection so no single area is used twice in a row. Swab with alcohol and let it dry for 10 seconds before injecting.

3D anatomical map showing abdomen (2 inches from navel), outer anterior thigh, and upper arm subcutaneous injection zones

Zone 01

Abdomen

≥ 2 in away from navel

Zone 02

Outer Thigh

Middle third, anterior-lateral

Zone 03

Upper Arm

Posterior / outer tricep pad

Pinch & Needle Angle

90° · 4–8 mm (31 G) short needle

Standard U-100 insulin syringe: pinch a light fold and insert straight in at 90°.

45° · 12.7 mm (1/2 in) needle

Longer needle or leaner area: pinch a 1-inch fold and enter at 45° into fat.

Aseptic Injection Checklist

• Use a brand-new sterile U-100 syringe for every draw (never reuse needles).

• Swab both the vial rubber stopper and injection site with 70% isopropyl alcohol and let dry.

• Rotate clockwise around the abdomen or alternate left/right thigh to prevent lipohypertrophy.

Lyophilized Powder (Unmixed)

Freezer −20 °C Long-Term · Fridge Short-Term

Unmixed freeze-dried vials stay stable for months in the refrigerator and 1–2+ years at −20 °C (0 °F) in the dark. Let the vial warm to room temperature before opening.

Reconstituted Liquid (Mixed)

Refrigerate 2–8 °C (36–46 °F) · Use Within 30 Days

Keep refrigerated and out of light once mixed with bacteriostatic water. Never freeze reconstituted liquid — ice crystals shear the dissolved peptide chains.

Pharmacology & Evidence

Mechanism & Clinical Research

How It Works

Tesamorelin is a stabilized GHRH(1-44) analog that increases GH pulse amplitude and downstream IGF-1 and has been shown to reduce visceral adipose tissue in controlled trials. Ipamorelin activates GHS-R1a to trigger the pulse and inhibit somatostatin, producing a GHRH + GHRP synergy similar to CJC/ipamorelin but with the longer-acting and clinically dosed tesamorelin as the GHRH component.

Common Dosing References

subcutaneous

750mcg-1.5mg · Daily at bedtime

8-12 weeks

subcutaneous

1.5-2.25mg · Daily at bedtime

12-26 weeks

Research use only. Not medical advice.

What The Research Shows

  1. 2010

    Tesamorelin for visceral adiposity (pooled phase 3)

    Tesamorelin 2 mg daily reduced visceral adipose tissue by ~15% over 26 weeks versus placebo in HIV lipodystrophy

  2. 2012

    Tesamorelin and cognition in older adults

    Twenty weeks of tesamorelin improved executive function in healthy older adults and those with mild cognitive impairment

Regulatory Status

Research compound; not FDA-approved. Tesamorelin alone is approved (Egrifta) for HIV-associated lipodystrophy; the blend with ipamorelin has no approved indication.

Clinical Profile

Potential Benefits

  • Visceral and abdominal fat reduction
  • Pulsatile GH and IGF-1 support
  • Lean mass preservation during caloric deficit
  • Improved sleep quality
  • Possible cognitive benefits reported with tesamorelin in older adults
  • Lower per-dose tesamorelin requirement than monotherapy

Reported Side Effects

  • Injection site redness, itching, or swelling
  • Joint pain and stiffness
  • Peripheral edema and water retention
  • Headache
  • Numbness or tingling (paresthesia)
  • Elevated blood glucose or reduced insulin sensitivity (monitor)

Provider Directory

Confirmed Clinics & Sourcing

Sourcing Notes

Pre-mixed 15 mg vials are sold by research vendors; verify both peptides are listed on the COA with the 2:1 ratio. Tesamorelin is relatively unstable once reconstituted — use within 2-3 weeks refrigerated.

Free Guide

Get Tesamorelin + Ipamorelin Blend research updates

New studies, regulatory changes and sourcing notes on the peptides you follow. One email a week, no spam.

Free. No spam. Unsubscribe anytime. From GLP1Search.

Find peptide-aware clinics

Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.

Search Local Clinics